A comparison of two medicines for low fluid in womb during late pregnancy and their effects on mother and baby

A comparative study of Oral L-arginine versus oral Sildenafil citrate in treatment of oligohydramnios between 32-37 weeks of pregnancy and its correlation with feto- maternal outcomes. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113703

Enrollment

200

Registered

2026-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O269- Pregnancy related conditions, unspecified

Interventions

Intervention1: Oral L-arginine: Oral L-arginine will be administered during 32-37 weeks of pregnancy to increase Amniotic Fluid Index Control Intervention1: Oral Sildenafil Citrate: Oral Sildenafil Ci

Eligibility

Inclusion criteria

Inclusion criteria: 1. Singleton pregnancy 2. Gestational age between 32 to 37 weeks 3. AFI less than 5 cm 4. Willingness to provide informed consent

Exclusion criteria

Exclusion criteria: 1. History of previous cesarean section 2. Multiple gestation 3. Presence of congenital fetal anomalies 4. Prior treatment for oligohydramnios

Design outcomes

Primary

Measure	Time frame
To compare the improvement in Amniotic Fluid IndexTimepoint: Assessment will be done after 4-8 weeks of drug administration	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Amardeep Tembhare

Datta Meghe Institute of Higher Education and Research

jspobgn@gmail.com9822439490

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026